- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
Patent holdings for IPC class A61K 31/551
Total number of patents in this class: 3460
10-year publication summary
|
285
|
232
|
230
|
258
|
269
|
270
|
238
|
274
|
266
|
197
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Woolsey Pharmaceuticals, Inc. | 80 |
53 |
| Boehringer Ingelheim International GmbH | 4485 |
46 |
| Novartis AG | 10175 |
43 |
| Merck Sharp & Dohme LLC | 3738 |
41 |
| Bristol-myers Squibb Company | 4764 |
37 |
| Dana-Farber Cancer Institute, Inc. | 2669 |
36 |
| Nippon Chemiphar Co., Ltd. | 225 |
32 |
| Kowa Company, Ltd. | 1243 |
31 |
| Takeda Pharmaceutical Company Limited | 2699 |
29 |
| GW Research Limited | 147 |
28 |
| F. Hoffmann-La Roche AG | 7800 |
27 |
| Gilead Sciences, Inc. | 2242 |
27 |
| The Regents of the University of California | 20842 |
26 |
| Genentech, Inc. | 4119 |
23 |
| Alkermes Pharma Ireland Limited | 255 |
23 |
| Centre National de La Recherche Scientifique | 11077 |
22 |
| Hoffmann-La Roche Inc. | 3825 |
21 |
| Merck Patent GmbH | 5739 |
21 |
| Janssen Pharmaceutica N.V. | 3160 |
18 |
| Arvinas Operations, Inc. | 247 |
18 |
| Other owners | 2858 |